This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Living Large

Basically the entire planet is the company's bright spot. Pinchuk said sales remain strong in Asia and yes, even in Europe. He was especially enthusiastic about China since, unlike America where there are 300 million cars on average 11 year old, China has 60 million cars, most of which are brand new. That means the coming boom in auto repair has yet to begin and Snap-on is positioning itself to become a dominant player.

Cramer once again praised Snap-on for proving that quality products can indeed be made in America. He continued his recommendation of the stock.

Know Your IPO

In the "Know Your IPO" segment, Cramer followed up on a few recent initial public offerings to separate the good from the bad and the ugly. He said Thursday's IPO of dollar store chain Five Below (FIVE - Get Report) rallied as expected, giving investors a 53% gain. But they must now keep their discipline and take profits.

So what of other recent IPOs? Cramer said Synacor (SYNC - Get Report) and Supernus Pharmaceuticals (SUPN - Get Report) have both been winners and investors need to take a victory lap and take profits. Synacor is up 160% since its IPO, while Supernus has delivered a 197% gain.

In the loser's corner, Cramer singled out Ignite Restaurant Group (IRG - Get Report), which announced "accounting irregularities," and WageWorks (WAGE), a stock that's now "priced for perfection." Cramer said both of these stocks need to be sold with prejudice.

Finally, Cramer noted Merrimack Pharmaceuticals (MACK - Get Report), a recent IPO that's still worth buying. He said that while speculative, Merrimack concentrates on orphan drugs that often receive special treatment at the Food and Drug Administration. The company is also partnering with Sanofi-Aventis (SNY) on a breast cancer treatment that could be a $1.3 billion opportunity.

Investing in Merrimack is playing FDA approval roulette, noted Cramer, but the stock is cheap enough that the company only needs one of its drugs to win in order to rewards shareholders. He said there's no catalyst for the stock, so there's no hurry to get in now.

Lightning Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

American Capital Agency (AGNC): "They keep doing equity offerings, but they're working so I'll stick with it."
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FIVE $35.07 -0.62%
IRG $4.85 -1.42%
MACK $9.60 1.80%
SNA $161.89 0.11%
SYNC $1.45 6.62%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs